Form 8-K - Current report:
SEC Accession No. 0000950170-24-139667
Filing Date
2024-12-23
Accepted
2024-12-23 16:55:56
Documents
15
Period of Report
2024-12-22
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K rapt-20241222.htm   iXBRL 8-K 63291
2 EX-4.1 rapt-ex4_1.htm EX-4.1 157624
3 EX-10.1 rapt-ex10_1.htm EX-10.1 927778
4 EX-10.2 rapt-ex10_2.htm EX-10.2 376697
5 EX-10.3 rapt-ex10_3.htm EX-10.3 216023
  Complete submission text file 0000950170-24-139667.txt   1864264

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT rapt-20241222.xsd EX-101.SCH 25974
17 EXTRACTED XBRL INSTANCE DOCUMENT rapt-20241222_htm.xml XML 4930
Mailing Address 561 ECCLES AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 561 ECCLES AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 489-9000
RAPT Therapeutics, Inc. (Filer) CIK: 0001673772 (see all company filings)

EIN.: 473313701 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38997 | Film No.: 241574604
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)